Janux drops its second project

Janux has been quiet for a while now on its second project, JANX008, and now it’s official: the company has discontinued the asset. The group said on Monday evening that the dual-masked EGFR-targeting T-cell engager hadn’t shown sufficient clinical activity to support further development. The signs for JANX008 hadn’t looked great since February 2024, when the company reported just one partial response among 11 solid tumour patients in a phase 1 trial. Janux had promised an update in 2025, but data never materialised. The company’s priority is its single-masked PSMA-targeting T-cell engager, JANX007, but data released in December disappointed, and the group’s stock is yet to recover. Further back in the pipeline, the company just started a phase 1 trial of a dual-masked PSMA project, JANX014; while JANX013, which combines PSMA with CD28 co-stimulation, is expected to hit the clinic this year. Janux ultimately hopes to combine JANX013 with its T-cell engagers to improve patients’ T-cell responses. However, things have gone quiet on a TROP2-targeting dual-masked T-cell engager that was resurrected last year. Janux should be applauded for killing a lacklustre project early, but it’s another setback for a company that’s struggled of late.

Janux’s oncology pipeline

Source: OncologyPipeline.